XML 62 R50.htm IDEA: XBRL DOCUMENT v3.20.2
Business Segment Information Business Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Mar. 31, 2020
Segment Reporting Information [Line Items]          
Revenues $ 756,132 $ 736,840 $ 1,425,064 $ 1,433,643  
Segment operating income 141,263 126,733 255,264 236,821  
Restructuring Charges [1] (76) 636 90 2,943  
Amortization of acquired intangible assets [2] 21,955 18,952 39,455 35,901  
Business Combination, Acquisition Related Costs [3] 1,135 1,947 2,421 3,864  
Impact of TCJA [4] 384 1,016 554 2,786  
Net loss on divestiture of businesses [2] (5) 50 5 2,476  
Amortization of inventory and property step-up to fair value [2] 714 446 1,317 1,181  
COVID-19 incremental costs [5] 4,539 0 13,209 0  
Assets 5,492,567   5,492,567   $ 5,425,582
Life Sciences          
Segment Reporting Information [Line Items]          
Revenues 115,658 98,650 232,570 195,435  
Segment operating income 46,433 32,315 94,894 65,354  
Applied Sterilization Technologies          
Segment Reporting Information [Line Items]          
Revenues 169,547 152,907 321,909 307,193  
Segment operating income 76,835 65,386 140,790 133,421  
Assets 2,850,052   2,850,052   2,720,205
Corporate          
Segment Reporting Information [Line Items]          
Segment operating income (58,155) (50,956) (110,522) (106,353)  
Segment operating income          
Segment Reporting Information [Line Items]          
Revenues 756,132 736,840 1,425,064 1,433,643  
Segment operating income 169,909 149,780 312,315 285,972  
Healthcare [Member] [Member]          
Segment Reporting Information [Line Items]          
Revenues 470,927 485,283 870,585 931,015  
Segment operating income 104,796 103,035 187,153 193,550  
Healthcare and Life Sciences [Member]          
Segment Reporting Information [Line Items]          
Assets 2,642,515   2,642,515   $ 2,705,377
Other foreign locations [Member]          
Segment Reporting Information [Line Items]          
Revenues 189,593 183,568 352,444 354,111  
UNITED STATES          
Segment Reporting Information [Line Items]          
Revenues 549,449 538,101 1,041,157 1,049,253  
UNITED KINGDOM          
Segment Reporting Information [Line Items]          
Revenues 17,090 15,171 31,463 30,279  
Consumable revenues [Member] | Life Sciences          
Segment Reporting Information [Line Items]          
Revenues 55,793 42,540 114,635 86,569  
Consumable revenues [Member] | Healthcare [Member] [Member]          
Segment Reporting Information [Line Items]          
Revenues 122,797 116,033 206,551 232,115  
Sales Revenue, Services, Net [Member] | Life Sciences          
Segment Reporting Information [Line Items]          
Revenues 30,624 29,648 58,264 55,635  
Sales Revenue, Services, Net [Member] | Healthcare [Member] [Member]          
Segment Reporting Information [Line Items]          
Revenues 216,457 216,619 404,279 425,414  
Capital equipment revenues [Member] | Life Sciences          
Segment Reporting Information [Line Items]          
Revenues 29,241 26,462 59,671 53,231  
Capital equipment revenues [Member] | Healthcare [Member] [Member]          
Segment Reporting Information [Line Items]          
Revenues $ 131,673 $ 152,631 $ 259,755 $ 273,486  
[1] For more information regarding our restructuring efforts refer to Note 2 titled, "Restructuring".
[2] For more information regarding our recent acquisitions and divestitures refer to our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020.
[3] Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions.
[4] Costs incurred in connection with the Redomiciliation.
[5] COVID-19 incremental costs includes the additional costs attributable to COVID-19 such as enhanced cleaning protocols, personal protective equipment for our employees, event cancellation fees, and payroll costs associated with our response to COVID-19, net of any government subsidies available.